title: A radiobiological model for the relative biological effectiveness of high-dose-rate 252Cf brachytherapy.
abstract: While there is significant clinical experience using both low- and high-dose-rate 252Cf brachytherapy, there are minimal data regarding values for the neutron relative biological effectiveness (RBE) with both modalities. The aim of this research was to derive a radiobiological model for 252Cf neutron RBE and to compare these results with neutron RBE values used clinically in Russia. The linear-quadratic (LQ) model was used as the basis to characterize cell survival after irradiation, with identical cell killing rates (S(N) = S(gamma)) between 252Cf neutrons and photons used for derivation of RBE. Using this equality, a relationship among neutron dose and LQ radiobiological parameter (i.e., alpha(N), beta(N), alpha(gamma), beta(gamma)) was obtained without the need to specify the photon dose. These results were used to derive the 252Cf neutron RBE, which was then compared with Russian neutron RBE values. The 252Cf neutron RBE was determined after incorporating the LQ radiobiological parameters obtained from cell survival studies with fast neutrons and teletherapy photons. For single-fraction high-dose-rate neutron doses of 0.5, 1.0, 1.5 and 2.0 Gy, the total biologically equivalent doses were 1.8, 3.4, 4.7 and 6.0 RBE Gy with 252Cf neutron RBE values of 3.2, 2.9, 2.7 and 2.5, respectively. Using clinical data for late-responding reactions from 252Cf, Russian investigators created an empirical model that predicted high-dose-rate 252Cf neutron RBE values ranging from 3.6 to 2.9 for similar doses and fractionation schemes and observed that 252Cf neutron RBE increases with the number of treatment fractions. Using these relationships, our results were in general concordance with high-dose-rate 252Cf RBE values obtained from Russian clinical experience.
authors.affiliation: Department of Radiation Oncology, Tufts-New England Medical Center, Boston, MA 02111, USA. mrivard@tufts-nemc.org
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Rivard
authors.forename: Christopher S
authors.initials: CS
authors.lastname: Melhus
authors.forename: Heather D
authors.initials: HD
authors.lastname: Zinkin
authors.forename: Liza J
authors.initials: LJ
authors.lastname: Stapleford
authors.forename: Krista E
authors.initials: KE
authors.lastname: Evans
authors.forename: David E
authors.initials: DE
authors.lastname: Wazer
authors.forename: Anna
authors.initials: A
authors.lastname: Odlozilíková
mesh_terms: D000818:Animals; D001822:Body Burden; D001918:Brachytherapy / Q000379:methods*; D002142:Californium / Q000627:therapeutic use*; D002470:Cell Survival / Q000528:radiation effects*; D003198:Computer Simulation; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000532:radiotherapy*; D011853:Radiobiology / Q000379:methods; D011874:Radiometry / Q000379:methods; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D011881:Radiotherapy, Computer-Assisted / Q000379:methods*; D012062:Relative Biological Effectiveness; D016896:Treatment Outcome
chemical_list: D002142:Californium